See more : Jiangsu Xiuqiang Glasswork Co., Ltd. (300160.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Bavarian Nordic A/S (BVNRY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bavarian Nordic A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zeder Investments Ltd. (ZED.JO) Income Statement Analysis – Financial Results
- Clearday, Inc. (CLRD) Income Statement Analysis – Financial Results
- Orchid Pharma Limited (ORCHPHARMA.NS) Income Statement Analysis – Financial Results
- Canadian General Investments, Limited (CGRIF) Income Statement Analysis – Financial Results
- PSI Software AG (PSSWF) Income Statement Analysis – Financial Results
Bavarian Nordic A/S (BVNRY)
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.06B | 3.15B | 1.90B | 1.85B | 662.49M | 500.62M | 1.37B | 1.01B | 1.02B | 1.22B | 1.21B | 1.02B | 523.60M | 314.07M | 74.78M | 208.81M | 332.10M | 175.29M | 247.60M | 164.78M | 504.64M | 121.08M | 0.00 |
| Cost of Revenue | 2.46B | 1.45B | 1.33B | 1.20B | 354.76M | 255.12M | 290.62M | 297.79M | 415.14M | 495.08M | 484.71M | 513.55M | 403.39M | 444.47M | 140.10M | 196.66M | 55.12M | 110.80M | 132.23M | 70.25M | 187.19M | 56.45M | 0.00 |
| Gross Profit | 4.60B | 1.70B | 570.32M | 657.29M | 307.73M | 245.50M | 1.08B | 708.95M | 605.42M | 721.73M | 727.80M | 503.08M | 120.21M | -130.40M | -65.32M | 12.15M | 276.99M | 64.50M | 115.37M | 94.53M | 317.45M | 64.62M | 0.00 |
| Gross Profit Ratio | 65.18% | 53.99% | 30.05% | 35.48% | 46.45% | 49.04% | 78.79% | 70.42% | 59.32% | 59.31% | 60.02% | 49.49% | 22.96% | -41.52% | -87.34% | 5.82% | 83.40% | 36.79% | 46.60% | 57.37% | 62.91% | 53.37% | 0.00% |
| Research & Development | 2.35B | 1.18B | 399.16M | 341.42M | 409.28M | 386.30M | 518.41M | 463.17M | 386.81M | 478.93M | 496.61M | 357.44M | 261.72M | 210.83M | 163.98M | 129.65M | 134.96M | 39.28M | 114.38M | 120.44M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 419.85M | 376.02M | 292.92M | 278.15M | 173.42M | 179.96M | 168.06M | 174.21M | 174.79M | 181.02M | 156.99M | 137.76M | 133.40M | 104.58M | 91.48M | 92.04M | -1.57M | -76.37M | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Selling & Marketing | 331.58M | 212.93M | 191.78M | 285.78M | 53.48M | 33.73M | 39.88M | 38.56M | 42.27M | 45.11M | 40.78M | 39.57M | 33.35M | 28.28M | 20.41M | 22.51M | 2.58M | 77.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 751.43M | 588.96M | 484.70M | 563.93M | 226.89M | 213.68M | 207.94M | 212.77M | 217.06M | 226.13M | 197.77M | 177.32M | 166.75M | 132.86M | 111.89M | 92.04M | 1.00M | 819.00K | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -627.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.84M | 206.05M | 228.16M | 45.37M | 120.44M | 60.42M | 59.88M | 71.53M |
| Operating Expenses | 3.11B | 1.77B | 883.86M | 277.70M | 636.18M | 599.98M | 726.34M | 675.94M | 603.87M | 705.06M | 694.38M | 534.76M | 428.48M | 343.69M | 275.87M | 235.53M | 342.01M | 268.26M | 235.14M | 176.85M | 103.41M | 91.27M | 93.48M |
| Cost & Expenses | 5.01B | 3.22B | 2.21B | 1.47B | 990.93M | 855.10M | 1.02B | 973.74M | 1.02B | 1.20B | 1.18B | 1.05B | 831.87M | 788.16M | 415.97M | 432.19M | 397.13M | 379.06M | 367.37M | 247.10M | 290.60M | 147.73M | 93.48M |
| Interest Income | 40.21M | 26.00K | 1.74M | 193.00K | 602.00K | 842.00K | 644.00K | 272.00K | 38.00K | 12.00K | 29.00K | 667.00K | 21.65M | 4.19M | 7.76M | 40.09M | 25.71M | 4.36M | 19.67M | 9.77M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.52M | 119.69M | 152.06M | 177.00M | 18.49M | 14.53M | 5.68M | 7.06M | 6.53M | 6.28M | 6.49M | 7.96M | 9.76M | 13.54M | 17.81M | 40.09M | 2.13M | 2.27M | 16.32M | 4.17M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 553.82M | 399.25M | 387.69M | 344.08M | 57.05M | 41.64M | 106.81M | 44.08M | 43.53M | 44.95M | 46.22M | 56.45M | 53.88M | 49.74M | 49.23M | 48.34M | 40.14M | 17.95M | 15.39M | 18.26M | 12.93K | 5.13M | 3.60M |
| EBITDA | 2.14B | 395.40M | 85.94M | 819.13M | -269.21M | -300.47M | 387.63M | 91.98M | 127.69M | 115.58M | 58.92M | 15.69M | -234.24M | -420.16M | -273.23M | -175.05M | -36.06M | -184.58M | -84.71M | -82.32M | 214.05M | -21.52M | -89.88M |
| EBITDA Ratio | 30.33% | 12.55% | 6.59% | 43.72% | -39.15% | -55.51% | 25.19% | 11.20% | 12.45% | 5.40% | 5.28% | 2.69% | -44.45% | -133.78% | -353.15% | -83.83% | -2.48% | -105.30% | -34.21% | -49.96% | 42.42% | -17.77% | 0.00% |
| Operating Income | 1.50B | -3.85M | -263.31M | 449.62M | -316.43M | -354.48M | 353.19M | 33.01M | 1.55M | 16.68M | 33.42M | -31.68M | -308.26M | -474.09M | -341.18M | -223.39M | -65.03M | -203.77M | -119.77M | -82.32M | 214.04M | -26.65M | -93.48M |
| Operating Income Ratio | 21.28% | -0.12% | -13.87% | 24.27% | -47.76% | -70.81% | 25.78% | 3.28% | 0.15% | 1.37% | 2.76% | -3.12% | -58.87% | -150.95% | -456.23% | -106.98% | -19.58% | -116.24% | -48.37% | -49.96% | 42.41% | -22.01% | 0.00% |
| Total Other Income/Expenses | -19.60M | -240.94M | -119.54M | 618.38M | -16.30M | -2.15M | -50.91M | 6.54M | 76.08M | 47.69M | -27.21M | -17.04M | 11.88M | -9.35M | 10.05M | 26.25M | 25.71M | -1.03M | 3.35M | 5.60M | 3.59M | 936.00K | 2.54M |
| Income Before Tax | 1.48B | -331.61M | -454.43M | 281.98M | -344.75M | -356.64M | 302.28M | 39.55M | 77.63M | 64.36M | 6.20M | -48.73M | -296.38M | -483.44M | -331.13M | -183.30M | -50.49M | -204.79M | -116.42M | -76.72M | 217.63M | -25.71M | -90.94M |
| Income Before Tax Ratio | 21.00% | -10.52% | -23.94% | 15.22% | -52.04% | -71.24% | 22.06% | 3.93% | 7.61% | 5.29% | 0.51% | -4.79% | -56.60% | -153.93% | -442.79% | -87.78% | -15.20% | -116.83% | -47.02% | -46.56% | 43.13% | -21.24% | 0.00% |
| Income Tax Expense | 7.75M | 15.77M | 10.35M | 4.46M | 2.03M | 5.29M | 120.94M | 8.95M | 18.20M | 38.42M | 52.93M | 191.28M | 27.96M | 93.53M | 64.86M | 32.94M | 13.01M | -43.86M | -21.69M | -23.71M | 67.06M | -95.83M | 1.14M |
| Net Income | 1.48B | -347.38M | -464.78M | 277.52M | -346.78M | -361.93M | 181.34M | 30.60M | 59.43M | 25.94M | -46.73M | -240.00M | -268.42M | -389.91M | -266.28M | -150.36M | -59.97M | -158.04M | -94.73M | -53.01M | 150.57M | 70.12M | -92.09M |
| Net Income Ratio | 20.89% | -11.03% | -24.49% | 14.98% | -52.34% | -72.30% | 13.24% | 3.04% | 5.82% | 2.13% | -3.85% | -23.61% | -51.26% | -124.15% | -356.07% | -72.01% | -18.06% | -90.16% | -38.26% | -32.17% | 29.84% | 57.91% | 0.00% |
| EPS | 19.20 | -4.93 | -7.37 | 5.13 | -8.50 | -2.96 | 1.50 | 0.26 | 0.55 | 0.26 | -0.47 | -2.43 | -3.41 | -8.83 | -6.96 | -3.31 | -1.38 | -4.13 | -2.88 | -1.88 | 5.01 | 2.64 | -4.52 |
| EPS Diluted | 19.23 | -4.93 | -7.37 | 5.13 | -8.50 | -2.96 | 1.50 | 0.26 | 0.55 | 0.26 | -0.47 | -2.43 | -3.41 | -8.83 | -6.96 | -3.31 | -1.38 | -4.13 | -2.88 | -1.88 | 5.01 | 2.64 | -4.50 |
| Weighted Avg Shares Out | 76.83M | 70.42M | 63.10M | 54.05M | 40.81M | 122.32M | 119.95M | 114.13M | 105.42M | 99.96M | 98.96M | 98.96M | 78.62M | 44.14M | 38.25M | 45.39M | 43.42M | 38.31M | 32.84M | 28.19M | 30.07M | 26.61M | 20.38M |
| Weighted Avg Shares Out (Dil) | 76.71M | 70.42M | 63.10M | 54.05M | 40.81M | 122.32M | 120.91M | 115.03M | 108.47M | 101.79M | 98.96M | 98.96M | 78.62M | 44.14M | 38.25M | 45.39M | 43.42M | 38.31M | 32.84M | 28.19M | 30.07M | 26.61M | 20.45M |
Bavarian Nordic Provides Update on RSV Vaccine Program
COPENHAGEN, Denmark, July 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) today announced that its Phase 3 clinical trial of MVA-BN® RSV, a respiratory syncytial virus (RSV) vaccine candidate for adults ≥60 years of age did not meet all the...
Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race
Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 demonstrated impressive seroresponse rates and durability, with future data releases from Bavarian Nordic's...
People at high risk to mpox should get 2 doses of Bavarian Nordic vaccine, US CDC says
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic's Jynneos vaccine, based on new evidence from a U.S. study showing that two doses were more effective...
Bavarian Nordic A/S (BVNKF) Q1 2023 Earnings Call Transcript
Call Start: 08:00 January 1, 0000 8:50 AM ET Bavarian Nordic A/S (OTCPK:BVNKF) Q1 2023 Earnings Conference Call May 9, 2023 08:00 ET Company Participants Rolf Sorensen - Investor Relations Paul Chaplin - President & Chief Executive Officer Henrik Juuel...
Mpox outbreak was wake-up call for smallpox preparation, vaccine maker Bavarian Nordic says
Bavarian Nordic plans to sharply scale up production of its Jynneos vaccine to prepare for a smallpox emergency, CEO Paul Chaplin said.
Bavarian Nordic A/S (BVNKF) Q3 2022 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Rolf Sorensen - Investor Relations Henrik Juuel - Executive Vice President, CFO Paul Chaplin - President and Chief Executive Officer Conference Call Participants...
Bavarian Nordic shares jump after reaching smallpox, monkeypox vaccine deal extension
Shares of BAVA, +10.04% jumped 11% as the drugmaker said it signed a contract amendment with Public Health Canada that's valued at up to $434 million over ten years. Under the new contract amendment, the majority of the confirmed order...
Bavarian Nordic A/S Could Post A Strong Comeback
Bearish sentiment weighed heavily on the biotech industry and Bavarian Nordic A/S. There is reason for optimism given the current opportunities offered by Monkeypox, Ebola and Covid-19.
Bavarian Nordic A/S (BVNKF) CEO Paul Chaplin on Q2 2022 Results - Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q2 2022 Earnings Conference Call August 24, 2022 8:00 AM ET Company Participants Rolf Sass – Investor Relations Paul Chaplin – President and Chief Executive Officer Henrik Juuel – Executive Vice President Conference Call Participants Thomas...
3 Top Monkeypox Stocks to Buy Right Now
With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts.
Source: https://incomestatements.info
Category: Stock Reports